Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

A G protein-coupled receptor is essential for Schwann cells to initiate myelination.
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
Genmab announces results of ofatumumab Phase II study in multiple sclerosis
Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies.
UCSF Seminar: "Antibody Repertoire Sequencing"
Useful Links
Characterization of CD56bright NK cells in daclizumab HYP-treated RRMS patients
Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and Remand for Further Review
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
Treatment of neurological injury with thymosin β4.
Rituximab and multiple sclerosis.
Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse-Remitting Multiple Sclerosis
Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis.
Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study.
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis.
Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells.
Biogen Idec submits application to FDA for approval of PLEGRIDY™ (peginterferon beta-1a) in multiple sclerosis
Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.
Effect of Glatiramer Acetate on Peripheral Blood Brain-Derived Neurotrophic Factor and Phosphorylated TrkB Levels in Relapsing-Remitting Multiple Sclerosis.
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.
Forward Pharma Receives Decision to Grant From EPO for DMF Patent in Europe
Treatment of progressive multiple sclerosis: what works, what does not, and what is needed.
Immunosuppressive properties of mesenchymal stem cells: advances and applications.
Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis.

Pages